(NYSE: AZN) today introduced
Complete the Course,
a creative education program to support patients taking BRILINTA
(ticagrelor). Patients who enroll in the
Complete the Course
program receive support services across multiple channels to help them stay on their full course of BRILINTA therapy. One important support resource now available is
Access My BRILINTA,
which provides time-saving prescription access and affordability information to patients and healthcare providers.
Please read full Prescribing Information, including Boxed WARNINGS, and Medication Guide. Additional information can be found at www.brilintatouchpoints.com. (Photo: AstraZeneca)
Complete the Course was created specifically to address patient preference for how they receive information about their medication as they transition from hospital to home. A recent nationwide patient survey showed that patients with ACS value robust, multi-channel communication to learn more about the medication prescribed. The survey was sponsored by AstraZeneca and conducted by Ipsos Public Affairs.
“Cardiologists have a tremendous responsibility to not only provide the best possible care for their patients, but also to ensure that their patients receive complete information about their diagnosis and the importance of adherence to treatment,” stated James Ferguson, MD, Executive Director, Medical Affairs and Strategic Development, and Vice President for Global Medical Affairs. “With the combination of the BRILINTA
Complete the Course
program along with
Access My BRILINTA
, we are now able to provide a variety of resources to patients with ACS and healthcare providers to help ensure continuity and optimal delivery of care throughout the course of treatment.”
A nationwide patient survey was conducted in 201 patients with ACS. The patients with ACS were adults aged 60 years and older who have suffered a heart attack or have been diagnosed with ACS (including heart attack and chest pain), and have been prescribed some form of medication for treatment of their heart attack.